FME logo

Fresenius Medical Care AG Stock Price

XTRA:FME Community·€10.9b Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author

FME Share Price Performance

€39.45
-6.95 (-14.98%)
€45.12
Fair Value
€39.45
-6.95 (-14.98%)
12.6% undervalued intrinsic discount
€45.12
Fair Value
Price €39.45
AnalystConsensusTarget €45.12
AnalystLowTarget €32.00
AnalystHighTarget €67.00

FME Community Narratives

AnalystConsensusTarget·
Fair Value €45.12 12.6% undervalued intrinsic discount

Aging Demographics And Home Care Trends Will Shape Future Profit Opportunities

0users have liked this narrative
2users have commented on this narrative
18users have followed this narrative
AnalystLowTarget·
Fair Value €32 23.3% overvalued intrinsic discount

The Shift To Home Dialysis Will Erode Core Revenues

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value €65.4 39.7% undervalued intrinsic discount

Aging, Diabetes, And Digital Health Will Fortify Home Dialysis Care

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€45.12
12.6% undervalued intrinsic discount
Revenue
3.04% p.a.
Profit Margin
6.33%
Future PE
10.82x
Price in 2029
€52.69
€32
23.3% overvalued intrinsic discount
Revenue
3.01% p.a.
Profit Margin
6.26%
Future PE
7.72x
Price in 2029
€37.16
€65.4
39.7% undervalued intrinsic discount
Revenue
4.98% p.a.
Profit Margin
7.56%
Future PE
12.92x
Price in 2028
€75.2

Trending Discussion

Updated Narratives

FME logo

FME: Confirmed 2025 Guidance And Margin Progress Will Support Future Upside Potential

Fair Value: €45.12 12.6% undervalued intrinsic discount
18 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
FME logo

FME: Earnings Reset Will Clash With Rich P E And Margin Headwinds

Fair Value: €32 23.3% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FME logo

Aging, Diabetes, And Digital Health Will Fortify Home Dialysis Care

Fair Value: €65.4 39.7% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

0 Risks
5 Rewards

Fresenius Medical Care AG Key Details

€19.6b

Revenue

€14.6b

Cost of Revenue

€5.0b

Gross Profit

€4.1b

Other Expenses

€978.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 12, 2026
3.56
25.62%
4.98%
51.2%
View Full Analysis

About FME

Founded
1996
Employees
109916
CEO
Helen Giza
WebsiteView website
www.freseniusmedicalcare.com

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Recent FME News & Updates

Recent updates

No updates